# Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

> **NCT02246075** · PHASE2 · WITHDRAWN · sponsor: **FORUM Pharmaceuticals Inc**

## Conditions studied

- Alzheimer's Disease
- Dementia
- Cognition

## Interventions

- **DRUG:** EVP-6124

## Key facts

- **NCT ID:** NCT02246075
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2016-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Forum has decided not to proceed with this study at this time.
- **Last updated:** 2015-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246075, "Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02246075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*